NO20054005L - Nye arylpiperazinylforbindelser - Google Patents

Nye arylpiperazinylforbindelser

Info

Publication number
NO20054005L
NO20054005L NO20054005A NO20054005A NO20054005L NO 20054005 L NO20054005 L NO 20054005L NO 20054005 A NO20054005 A NO 20054005A NO 20054005 A NO20054005 A NO 20054005A NO 20054005 L NO20054005 L NO 20054005L
Authority
NO
Norway
Prior art keywords
new
arylpiperazinyl
compounds
adhd
migraine
Prior art date
Application number
NO20054005A
Other languages
English (en)
Other versions
NO20054005D0 (no
Inventor
Dale S Dhanoa
Dongli Chen
Oren Becker
Silvia Noiman
Sirinvasa Rao Cheruku
Yael Marantz
Anurag Sharadendu
Sharon Shachem
Alexander Heifetz
Pradyumna Mohanty
Boaz Inbal
Merav Ficman
Raphael Nudelman
Shay Bar-Haim
Original Assignee
Predix Pharmaceuticals Holding
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Predix Pharmaceuticals Holding filed Critical Predix Pharmaceuticals Holding
Publication of NO20054005D0 publication Critical patent/NO20054005D0/no
Publication of NO20054005L publication Critical patent/NO20054005L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32—One oxygen, sulfur or nitrogen atom
    • C07D239/42—One nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Rheumatology (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Foreliggende oppfinnelse angår 5-HT resepior agonister eller antagonister. Nye arylpiperazinyl sulfonamid forbindelsen representert ved formel (I) og synteser og anvendelser derav for å-behandle sykdommer som inkluderer de som formidles direkte eller indirekte av 5-HT reseptorer, er beskrevet. Slike tilstander inkluderer sentralnervesystem forstyrrelser slik som generell angst forstyrrelse, ADD/ADHD, neuronal skade, slag og migrene. Fremgangsmåter for fremstilling av og nye intermediater og farmasøytiske salter derav er også inkludert.
NO20054005A 2003-01-31 2005-08-29 Nye arylpiperazinylforbindelser NO20054005L (no)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US44398803P 2003-01-31 2003-01-31
US45829703P 2003-03-28 2003-03-28
US50352003P 2003-09-16 2003-09-16
US10/768,579 US7153858B2 (en) 2003-01-31 2004-01-30 Arylpiperazinyl compounds
PCT/US2004/002858 WO2004069794A2 (en) 2003-01-31 2004-02-02 New arylpiperazinyl compounds

Publications (2)

Publication Number Publication Date
NO20054005D0 NO20054005D0 (no) 2005-08-29
NO20054005L true NO20054005L (no) 2005-10-27

Family

ID=32854494

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20054005A NO20054005L (no) 2003-01-31 2005-08-29 Nye arylpiperazinylforbindelser

Country Status (11)

Country Link
US (3) US7153858B2 (no)
EP (1) EP1592425A4 (no)
JP (2) JP4787148B2 (no)
KR (1) KR20060010717A (no)
AU (1) AU2004209020B2 (no)
BR (1) BRPI0407175A (no)
CA (1) CA2513915C (no)
MA (1) MA27715A1 (no)
MX (1) MXPA05008212A (no)
NO (1) NO20054005L (no)
WO (1) WO2004069794A2 (no)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7153858B2 (en) * 2003-01-31 2006-12-26 Epix Delaware, Inc. Arylpiperazinyl compounds
US20050222175A1 (en) * 2004-03-31 2005-10-06 Dhanoa Dale S New piperidinylamino-thieno[2,3-D] pyrimidine compounds
US7612078B2 (en) * 2003-03-31 2009-11-03 Epix Delaware, Inc. Piperidinylamino-thieno[2,3-D] pyrimidine compounds
AR047759A1 (es) * 2003-09-26 2006-02-22 Vertex Pharma Derivados de fenil - piperazina como moduladores de receptores muscarnicos
US7488736B2 (en) * 2004-05-17 2009-02-10 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
US7598265B2 (en) * 2004-09-30 2009-10-06 Epix Delaware, Inc. Compositions and methods for treating CNS disorders
US7576211B2 (en) * 2004-09-30 2009-08-18 Epix Delaware, Inc. Synthesis of thienopyridinone compounds and related intermediates
US7407966B2 (en) * 2004-10-07 2008-08-05 Epix Delaware, Inc. Thienopyridinone compounds and methods of treatment
CA2595607C (en) 2005-01-25 2014-07-15 Epix Delaware, Inc. Substituted arylamine compounds and their use as 5-ht6 modulators
MX2007012242A (es) * 2005-03-29 2008-03-18 Johnson & Johnson Ciclohexan-1,4-diaminas sustituidas con piperacinilo.
CA2694621C (en) 2007-08-07 2015-01-06 Prosarix Limited Novel serotonergic modulators
TW200914020A (en) * 2007-08-28 2009-04-01 Lilly Co Eli Substituted piperazinyl pyrazines and pyridines as 5-HT7 receptor antagonists
US20090281112A1 (en) * 2008-05-08 2009-11-12 Fabre-Kramer Pharmaceuticals, Inc. Adatanserin and metabolites thereof for treatment of attention deficit disorder, anxiety, depression, sexual dysfunction, and other disorders
BRPI0912516A2 (pt) * 2008-05-08 2015-10-13 Fabre Kramer Pharmaceuticals Inc 3-hidróxi gepirona para o tratamento de distúrbio de défict de atenção e disfunção sexual
WO2010065743A2 (en) * 2008-12-03 2010-06-10 Nanotherapeutics, Inc. Bicyclic compounds and methods of making and using same
US8927553B2 (en) * 2009-08-10 2015-01-06 Daljit Singh Dhanoa Deuterium-enriched alkyl sulfonamides and uses thereof
US8530479B2 (en) * 2009-08-10 2013-09-10 Daljit Singh Dhanoa Deuterium-enriched alkyl sulfonamides
PL392436A1 (pl) 2010-09-17 2012-03-26 Adamed Spółka Z Ograniczoną Odpowiedzialnością Pochodne arylosulfonamidów do leczenia chorób odśrodkowego układu nerwowego
US9901827B2 (en) * 2015-01-06 2018-02-27 Spin Master Ltd. Methods and system relating to physical constructions and virtual representations
KR102571028B1 (ko) 2016-12-20 2023-08-28 래쉬파이 인코포레이티드 인공 속눈썹 연장부에 사용하는 어플리케이터 및 케이스
KR20210110177A (ko) 2019-01-14 2021-09-07 래쉬파이 인코포레이티드 속눈썹 연장물 및 그의 제조 및 사용 방법
CN211747241U (zh) 2019-10-03 2020-10-27 莱施菲公司 人造睫毛装置及睫毛延长装置
KR102447231B1 (ko) * 2020-05-29 2022-09-27 재단법인 대구경북첨단의료산업진흥재단 설폰아미드 유도체 및 이를 유효성분으로 함유하는 정신질환의 예방 또는 치료용 약학적 조성물
JP2023528545A (ja) * 2020-05-29 2023-07-04 テグ－キョンプク メディカル イノベーション ファウンデーション スルホンアミド誘導体およびそれを有効成分とする精神病の予防または治療に使用するための医薬組成物

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2722529A (en) * 1955-11-01 Amides of certain l-amevoalkyl-x-phenyl
DK101683A (da) * 1982-03-12 1983-09-13 Duphar Int Res Phenylpiperazinderivater og fremgangsmaade til fremstilling heraf
JPS5929665A (ja) * 1982-08-11 1984-02-16 Sumitomo Chem Co Ltd ピペラジン誘導体及びその酸付加塩
JP2556722B2 (ja) * 1988-02-18 1996-11-20 興和株式会社 新規なスルホンアミド化合物
DE3901814A1 (de) 1988-07-28 1990-02-01 Bayer Ag Substituierte aminomethylzetraline sowie ihre heterocyclischen analoga
US5300523A (en) 1988-07-28 1994-04-05 Bayer Aktiengesellschaft Substituted aminomethyltetralins and their heterocyclic analogues
FR2655988B1 (fr) * 1989-12-20 1994-05-20 Adir Cie Nouveaux derives de la napht-1-yl piperazine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent.
ZA929008B (en) 1991-12-13 1993-05-21 Bristol Myers Squibb Co Piperazinyl- and piperidinyl-cyclohexanols.
IT1266582B1 (it) * 1993-07-30 1997-01-09 Recordati Chem Pharm Derivati (di)azacicloesanici e diazacicloeptanici
JP3836892B2 (ja) * 1993-12-27 2006-10-25 トーアエイヨー株式会社 置換環状アミン化合物、その製造法及びそれを含有する循環器官用剤
EP0661266A1 (en) * 1993-12-27 1995-07-05 Toa Eiyo Ltd. Substituted cyclic amine compounds as 5HT2 antagonists
FR2722788B1 (fr) 1994-07-20 1996-10-04 Pf Medicament Nouvelles piperazides derivees d'aryl piperazine, leurs procedes de preparation, leur utilisation a titre de medicament et les compositions pharmaceutiques les comprenant
US5602124A (en) 1994-12-12 1997-02-11 Allelix Biopharmaceuticals, Inc. 5-HT2 receptor ligands
JPH09202764A (ja) 1996-01-24 1997-08-05 Chugai Pharmaceut Co Ltd ニトロ化合物
DZ2376A1 (fr) 1996-12-19 2002-12-28 Smithkline Beecham Plc Dérivés de sulfonamides nouveaux procédé pour leurpréparation et compositions pharmaceutiques les c ontenant.
ID27976A (id) 1998-06-19 2001-05-03 Lundbeck & Co As H 4,5,6 dan 7-indol dan turunan-turunan indolin, pembuatan dan penggunaannya
AR022303A1 (es) 1999-01-22 2002-09-04 Lundbeck & Co As H Derivados de piperidina, tetrahidropiridina y piperazina, su preparacion y utilizacion
GB9906624D0 (en) 1999-03-23 1999-05-19 Smithkline Beecham Plc Novel compounds
US6465467B1 (en) 1999-05-21 2002-10-15 Biovitrum Ab Certain aryl-aliphatic and heteroaryl-aliphatic piperazinyl pyrazines and their use in the treatment of serotonin-related diseases
US7361666B2 (en) 1999-05-25 2008-04-22 Sepracor, Inc. Heterocyclic analgesic compounds and methods of use thereof
US6635661B2 (en) 2000-05-25 2003-10-21 Sepracor Inc. Heterocyclic analgesic compounds and methods of use thereof
WO2001068604A2 (en) 2000-03-14 2001-09-20 Sepracor, Inc. 3-substituted piperidines comprising urea functionality, and methods of use thereof
WO2001092226A1 (en) 2000-05-25 2001-12-06 Sepracor, Inc. Heterocyclic analgesic compounds and method of use thereof
AU9087301A (en) 2000-09-11 2002-03-26 Sepracor Inc Ligands for monoamine receptors and transporters, and methods of use thereof
WO2002022579A2 (en) 2000-09-11 2002-03-21 Sepracor, Inc. Antipsychotic sulfonamide-heterocycles, and methods of use thereof
AU2002237704A1 (en) 2000-12-04 2002-06-18 Sepracor, Inc. Methods for the stereoselective synthesis of substituted piperidines
WO2002069973A1 (en) 2001-03-02 2002-09-12 Sepracor, Inc. Piperidine-piperazine ligand for neurotransmitter receptors
US7115607B2 (en) 2001-07-25 2006-10-03 Amgen Inc. Substituted piperazinyl amides and methods of use
US20030073681A1 (en) 2001-08-21 2003-04-17 Hauske James R. 2-substituted piperidines that are ligands for monoamine receptors and transporters
ATE396971T1 (de) * 2002-03-13 2008-06-15 Janssen Pharmaceutica Nv Sulfonylaminoderivate als neue inhibitoren von histondeacetylase
US7153858B2 (en) * 2003-01-31 2006-12-26 Epix Delaware, Inc. Arylpiperazinyl compounds
CA2595607C (en) 2005-01-25 2014-07-15 Epix Delaware, Inc. Substituted arylamine compounds and their use as 5-ht6 modulators

Also Published As

Publication number Publication date
AU2004209020A1 (en) 2004-08-19
NO20054005D0 (no) 2005-08-29
KR20060010717A (ko) 2006-02-02
WO2004069794A3 (en) 2004-11-04
US20070004742A1 (en) 2007-01-04
US20080027066A1 (en) 2008-01-31
US7491727B2 (en) 2009-02-17
WO2004069794A2 (en) 2004-08-19
EP1592425A4 (en) 2007-01-24
WO2004069794B1 (en) 2005-01-27
BRPI0407175A (pt) 2006-02-07
CA2513915A1 (en) 2004-08-19
JP2006516640A (ja) 2006-07-06
JP2011207904A (ja) 2011-10-20
JP4787148B2 (ja) 2011-10-05
WO2004069794A9 (en) 2004-12-09
CA2513915C (en) 2013-04-09
AU2004209020B2 (en) 2009-05-28
MXPA05008212A (es) 2006-01-17
AU2004209020A2 (en) 2004-08-19
US20040220192A1 (en) 2004-11-04
EP1592425A2 (en) 2005-11-09
US7153858B2 (en) 2006-12-26
MA27715A1 (fr) 2006-01-02
US7488731B2 (en) 2009-02-10

Similar Documents

Publication Publication Date Title
NO20054005L (no) Nye arylpiperazinylforbindelser
NO20055029D0 (no) Nye piperidinylamino-tieno[2,3-di]pyrimidinforbindelser
JP6337124B2 (ja) インダゾール及びその使用
EA200600049A1 (ru) Способы получения 3 - бензазепинов
NO20065814L (no) Thiendopyridinon forbindelser og fremgangsmater for behandling
NO20076344L (no) Piperazin-piperidin-antagonister og agonister av 5-HT1A-reseptoren
NO20052728L (no) Substituerte tricykliske gamma-karboliner som serotonin reseptor agonister og antagonister
NO20064156L (no) Indazolkarboksamidforbindelser som 5-HT4 receptoragonister
EA201000331A1 (ru) 1',3-двузамещенные 4-(арил-х-фенил)-1h-пиридин-2-оны
NO20080981L (no) Nitrocatechol-derivater som COMT-inhibitorer
EA200800430A1 (ru) Замещённые тетрагидро-1н-пиридо[4,3,b] индолы как агонисты и антагонисты серотониновых рецепторов
NO20072348L (no) Thienopyridinone sammensetninger og fremgangsmate for behandling
TW200836743A (en) Quinazolinone and fused pyrimidinone compounds and their use in treating sodium channel-mediated diseases or conditions
EA200701588A1 (ru) Способы получения замещённых фенилпиразолмочевин
NO20075406L (no) Pyrimidindionerivater som prokineticin-2-reseprorantagonister
NO20083197L (no) Substituert cinnolin-derivater som GABAA-reseptor modulatorer og metode for deres syntese
EA201000314A1 (ru) 1',3'-двузамещенные-4-фенил-3,4,5,6-тетрагидро-2h,1'h-[1,4']бипиридинил-2'-оны
DE602006019595D1 (de) Benzimidazoloncarbonsäureamidverbindungen als agonisten des 5-ht4-rezeptors
NO20084481L (no) Benzimidazolderivater og deres anvendelse til modulering av GABAA-reseptorkompleks
PE20081496A1 (es) Derivados de 2,5-dihidro-3-h-pirazolo[4,3-c]piridazin-3-ona sustituidos como antagonistas de los receptores cb1
JP2006524641A (ja) 置換されたインドリンおよびインドール誘導体
Meyer et al. Structure− Activity Studies for a Novel Series of N-(Arylethyl)-N-(1, 2, 3, 4-tetrahydronaphthalen-1-ylmethyl)-N-methylamines Possessing Dual 5-HT Uptake Inhibiting and α2-Antagonistic Activities
Tsotinis et al. Mapping the melatonin receptor. 7. Subtype selective ligands based on β-substituted N-acyl-5-methoxytryptamines and β-substituted N-acyl-5-methoxy-1-methyltryptamines
Berg et al. (R)-(+)-2-[[[3-(Morpholinomethyl)-2 H-chromen-8-yl] oxy] methyl] morpholine Methanesulfonate: A New Selective Rat 5-Hydroxytryptamine1B Receptor Antagonist
WO2012035123A1 (en) Arylosulfonamides for the treatment of cns diseases

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application